February 2026 Zillow Investor Presentation Legal Disclosure This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties, including, without limitation, statements regarding our future targets, the future performance and operation of our business, our business strategies and ability to translate such strategies into financial performance, the current and future ...

Some analysts expect Zillow will have strong revenue growth as the housing market improves. ...

Core Insights - The real estate sector has identified oversold stocks, presenting potential buying opportunities for undervalued companies [1] - The Relative Strength Index (RSI) is a key momentum indicator, with stocks considered oversold when the RSI is below 30 [1] Company Summaries - Wheeler Real Estate Investment Trust Inc (NASDAQ:WHLR) is listed among the major oversold players in the real estate sector [3] - Zillow Group Inc (NASDAQ:Z) has an RSI value of 26.7, indicating it is oversold, and its stock price has decreased by approximately 21% over the past month, reaching a 52-week low of $53.61 [4] - Zillow's stock closed at $54.97 after a 1.8% increase on the last trading day [4]

Core Insights - The real estate sector has several oversold stocks, presenting potential buying opportunities for undervalued companies [1] Group 1: Oversold Stocks - The Relative Strength Index (RSI) is a key indicator for identifying oversold conditions, typically when the RSI is below 30 [1] - Major oversold stocks in the real estate sector include Wheeler Real Estate Investment Trust Inc (NASDAQ:WHLR) and Zillow Group Inc (NASDAQ:Z) [2][3] - Zillow Group's stock has decreased approximately 21% over the past month, with an RSI value of 26.7, indicating it is oversold [4] Group 2: Stock Performance - Zillow Group's shares closed at $54.97 after a 1.8% increase on the last trading day [4] - The company is set to release its fourth-quarter and full-year 2025 financial results on February 10 [4]

Core Viewpoint - Atossa Therapeutics has reaffirmed its strong market position in the Duchenne Muscular Dystrophy (DMD) program following the reauthorization of the Rare Pediatric Disease Priority Review Voucher (PRV) Program, which allows for potential future PRV eligibility upon FDA approval of (Z)-endoxifen for DMD treatment [1][3] Group 1: Rare Pediatric Disease Designation - The Rare Pediatric Disease (RPD) designation is granted to drug candidates for serious or life-threatening diseases affecting individuals from birth to 18 years old, allowing for eligibility for a PRV upon FDA approval [2][4] - PRVs can be used for priority review of future applications or sold to other sponsors, with recent PRV sales ranging from $150 million to $200 million [2] Group 2: Company Statements and Insights - The renewal of the PRV program signals congressional recognition of the complexities and financial burdens in drug development, validating the potential of (Z)-endoxifen for DMD treatment [3] - Atossa's leadership emphasizes the urgent need for better treatment options for DMD beyond current therapies, highlighting (Z)-endoxifen's broader treatment approach [3] Group 3: Product and Market Potential - (Z)-endoxifen is a Selective Estrogen Receptor Modulator/Degrader (SERM/D) with a favorable safety profile and distinct pharmacology, currently not approved for any indication [6] - The company is advancing (Z)-endoxifen's development in both oncology and rare diseases, supported by a growing global intellectual property portfolio [7][8]

Group 1 - The Seattle-based real estate company, Zillow, announced workforce reductions that account for approximately 2% of its total headcount [1]

Core Insights - The stock markets are starting 2026 on a challenging note due to increasing macroeconomic uncertainties and geopolitical tensions, leading investors to seek safer options [1] Group 1 - Investors are becoming more selective in their investment choices amid the current market conditions [1] - Gary Alexander, with extensive experience in technology companies and startups, is actively contributing insights on industry trends [1]

Group 1 - The focus is on producing objective, data-driven research primarily about small- to mid-cap companies, which are often overlooked by many investors [1] - Occasionally, large-cap companies are analyzed to provide a broader perspective on the equity markets [1] Group 2 - No stock, option, or similar derivative positions are held in any of the companies mentioned, but there may be plans to initiate a beneficial long position in the near future [2] - The article expresses personal opinions and is not influenced by compensation from any company mentioned [2]

Group 1 - The focus is on producing objective, data-driven research primarily about small- to mid-cap companies, which are often overlooked by many investors [1] - Occasionally, large-cap companies are analyzed to provide a broader perspective on the equity markets [1] Group 2 - No stock, option, or similar derivative positions are held in any of the companies mentioned, but there may be plans to initiate a beneficial long position in the near future [2] - The article expresses personal opinions and is not influenced by compensation from any company mentioned [2]

Core Insights - Atossa Therapeutics has received Orphan Drug Designation from the FDA for (Z)-endoxifen to treat Duchenne muscular dystrophy (DMD), which is a significant milestone for the company in its development efforts for this serious disease [1][2] Group 1: Company Overview - Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies in oncology and other areas with high unmet medical needs [7] - The company's lead product candidate, (Z)-endoxifen, is being evaluated for its potential applications in oncology and rare diseases [5][7] - Atossa has a growing global intellectual property portfolio supporting the (Z)-endoxifen program, including multiple recently issued U.S. patents and numerous pending applications worldwide [6] Group 2: Product Information - (Z)-endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader (SERM/SERD) with demonstrated activity across multiple mechanisms of interest, showing a favorable safety profile distinct from tamoxifen [5] - The drug is not yet approved for any indication, and the company plans to continue engaging with the FDA as it advances its development efforts [2][5] Group 3: Disease Context - Duchenne Muscular Dystrophy (DMD) is a rare, progressive, X-linked neuromuscular disorder caused by mutations in the dystrophin gene, leading to severe symptoms and a substantial unmet medical need for effective treatments [4]